In summary, among the differing clinical and pathological characteristics in the two patient groups, factors such as age at menarche, menstrual status, molecular subtypes, Ki-67 levels, comorbidities, and others were influential in BC risk or prognosis. This evidence concerns the gene MKI67 and breast cancer.